Enhanced low density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy

Schrott, Helmut G.; Stein, Evan A.; Dujovne, Carlos A.; Davidson, Michael; Goris, George B.; Oliphant, Thomas H.; Phillips, Joann C.; Shawaryn, Gregory G.

doi:10.1016/s0002-9149(99)80523-2

Cited by 45 publications

(18 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[93][94][95][96][97][98][99] All trials were parallel arm RCTs that included a dietary run-in period and treatment for 4 to 24 weeks. A comparative effectiveness review found evidence of moderate strength that supported low-potency statins, combined with BAS, as being more effective than midpotency statin monotherapy for lowering LDL-C levels.…”

Section: Kr Sando and M Knightmentioning

confidence: 99%

Nonstatin Therapies for Management of Dyslipidemia: A Review

Sando¹,

Knight²

2015

Clinical Therapeutics

View full text Add to dashboard Cite

Section: Kr Sando and M Knightmentioning

confidence: 99%

Nonstatin Therapies for Management of Dyslipidemia: A Review

Sando¹,

Knight²

2015

Clinical Therapeutics

View full text Add to dashboard Cite

“…When combination therapy is required for lipid lowering, the LDL reduction with drug therapy is additive within normal dosing ranges. 21,35,36,[45][46][47][48][49][50][51]63,73,78,88,91,[94][95][96][97][98] For example, 20 mg of fluvastatin provides an approximate 20% LDL reduction as monotherapy. 36,[45][46][47][48][49][50][51][52][53][54][55] Niacin, 3 g, provides an approximate 21% LDL reduction as monotherapy.…”

Section: Resultsmentioning

confidence: 99%

Forecasting Patient Outcomes in the Management of Hyperlipidemia

Brier

Tornow²,

Ries

et al. 1999

Arch Intern Med

View full text Add to dashboard Cite

“…A decrease of LDL-C by at least 30% to 50% can medically be advantageous to patients at high risk of heart disease; however, it is difficult to reach this goal with statins alone. Recent clinical experiments have suggested that statins in combination with ezetimibe significantly decrease LDL-C levels in the serum of hypercholesterolemic patients, indicating greater hypolipidemic activity compared with statins alone (4,(30)(31)(32). Van Heek M, et al showed that co-administration of ezetimibe with simvastatin caused 44% to 57%, atorvastatin 50% to 60%, lovastatin 33% to 45% and pravastatin 34% to 41% decrease in plasma LDL-C levels (31).…”

Section: Discussionmentioning

confidence: 99%

Combination of Ezetimibe and Garlic Reduces Serum Lipids and Intestinal Niemann-Pick C1-like 1 Expression More Effectively in Hypercholesterolemic Mice

Mohammadi¹,

Vafaei²,

Moradi³

et al. 2015

Avicenna J Med Biochem

View full text Add to dashboard Cite

Background: Combination therapy plays an important role in the management of cardiovascular disease (CVD).Objectives: The aim of this experiment was to study the influence of garlic combined with ezetimibe on lipid profile as well as intestinal Niemann-Pick C1-like 1 (NPC1L1) expression in normal and hypercholesterolemic mice. Materials and Methods: A total of 40 mice were randomly divided into five groups: Group 1: hypercholesterolemic group (received 2% w/w cholesterol + 0.5% w/w cholic acid in their diet), Group 2: garlic group (hypercholesterolemic diet + 4% w/w garlic extract), Group 3: ezetimibe group (hypercholesterolemic diet + 0.005% w/w ezetimibe), Group 4: combination group (hypercholesterolemic diet + 0.005% w/w ezetimibe + 4% w/w garlic) and Group 5: control (chow only). Results: Serum low-density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) levels were significantly decreased in ezetimibe, garlic (both P < 0.05), and combination groups (P < 0.001). Also, triglycerides and very low-density lipoprotein-cholesterol (VLDL-C) were significantly lower in garlic and combination groups (P < 0.05). Liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), were also significantly decreased in garlic, ezetimibe (both P < 0.05) and combination groups (P < 0.001) in comparison with hypercholesterolemic animals. Analysis of semi quantitative RT-PCR results showed that the levels of NPC1L1 was also significantly less (P < 0.01) in the garlic, ezetimibe, and combination groups (P < 0.001) compared with the controls. Based on the results, the combination of garlic and ezetimibe can lower serum lipids and liver enzymes more effectively in hypercholesterolemic mice. Conclusions: This experiment revealed that a possible mechanism for the beneficial effects of garlic and ezetimibe combination in lowering plasma LDL-C and TC is inhibition of intestinal cholesterol absorption. More research might be necessary to determine the efficacy and the exact mechanism of this co-administration.

show abstract

Enhanced low density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy

Cited by 45 publications

References 19 publications

Nonstatin Therapies for Management of Dyslipidemia: A Review

Nonstatin Therapies for Management of Dyslipidemia: A Review

Forecasting Patient Outcomes in the Management of Hyperlipidemia

Combination of Ezetimibe and Garlic Reduces Serum Lipids and Intestinal Niemann-Pick C1-like 1 Expression More Effectively in Hypercholesterolemic Mice

Contact Info

Product

Resources

About